Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment
American Journal of Respiratory Cell and Molecular Biology · 2023
DOI: 10.1165/rcmb.2022-0264oc ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Respiratory Cell and Molecular Biology, 2023. Verfasst von Mohamed Abdelgied und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Human Development and. Hauptthemen laut MEDLINE: Cystic Fibrosis, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a pathological condition of unknown etiology that results from injury to the lung and an ensuing fibrotic response that leads to the thickening of the alveolar walls and obliteration of the alveolar space. The pathogenesis is not clear, and there are currently no effective therapies for IPF. Small airway disease and mucus accumulation are prominent features in IPF lungs, similar to cystic fibrosis lung disease. The ATP12A gene encodes the α-subunit of the nongastric H+, K+-ATPase, which functions to acidify the airway surface fluid and impairs mucociliary transport function in patients with cystic fibrosis. It is hypothesized that the ATP12A protein may play a role in the pathogenesis of IPF. The authors’ studies demonstrate that ATP12A protein is overexpressed in distal small airways from the lungs of patients with IPF compared with normal human lungs. In addition, overexpression of the ATP12A protein in mouse lungs worsened bleomycin induced experimental pulmonary fibrosis. This was prevented by a potassium competitive proton pump blocker, vonoprazan. These data support the concept that the ATP12A protein plays an important role in the pathogenesis of lung fibrosis. Inhibition of the ATP12A protein has potential as a novel therapeutic strategy in IPF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics and Human Development and.
- Division of Pulmonary and Critical Care Medicine.
- Department of Pharmacology and Toxicology and.
- Department of Medicine, College of Human Medicine, Michigan State University, Grand Rapids, Michigan.
- Research and Development, and.
- Richard Devos Heart and Lung Transplant Program, Spectrum Health, Grand Rapids, Michigan.
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Abdelgied, M., Uhl, K., Chen, O. G., Schultz, C., Tripp, K., Peraino, A. M., Paithankar, S., Chen, B., Tamae Kakazu, M., Castillo Bahena, A., Jager, T. E., Lawson, C., Chesla, D. W., Pestov, N., Modyanov, N. N., Prokop, J., Neubig, R. R., Uhal, B. D., Girgis, R. E., & Li, X. (2023). Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment. American Journal of Respiratory Cell and Molecular Biology. https://doi.org/10.1165/rcmb.2022-0264oc
Vancouver
Abdelgied M, Uhl K, Chen OG, Schultz C, Tripp K, Peraino AM, et al. Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment. American Journal of Respiratory Cell and Molecular Biology. 2023. doi:10.1165/rcmb.2022-0264oc
BibTeX
@article{Abdelgied2023,
author = {Abdelgied, Mohamed and Uhl, Katie and Chen, Oliver G and Schultz, Chad and Tripp, Kaylie and Peraino, Angela M and Paithankar, Shreya and Chen, Bin and Tamae Kakazu, Maximiliano and Castillo Bahena, Alicia and Jager, Tara E and Lawson, Cameron and Chesla, Dave W and Pestov, Nikolay and Modyanov, Nikolai N and Prokop, Jeremy and Neubig, Richard R and Uhal, Bruce D and Girgis, Reda E and Li, Xiaopeng},
title = {Targeting ATP12A, a Nongastric Proton Pump α Subunit, for Idiopathic Pulmonary Fibrosis Treatment},
journal = {American Journal of Respiratory Cell and Molecular Biology},
year = {2023},
doi = {10.1165/rcmb.2022-0264oc}
}
EUVIMED